LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Kura Oncology Inc

Затворен

СекторЗдравеопазване

6.01 1.52

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

5.88

Максимум

6.2

Ключови измерители

By Trading Economics

Приходи

-38M

-57M

Продажби

-40M

14M

EPS

-0.66

Марж на печалбата

-407.067

Служители

192

EBITDA

-48M

-65M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+279.83% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.4M

527M

Предишно отваряне

4.49

Предишно затваряне

6.01

Настроения в новините

By Acuity

50%

50%

177 / 382 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Kura Oncology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.05.2025 г., 19:39 ч. UTC

Значими двигатели на пазара

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16.05.2025 г., 23:18 ч. UTC

Топ новини

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16.05.2025 г., 22:30 ч. UTC

Топ новини

U.S. Loses Last Triple-A Credit Rating -- Update

16.05.2025 г., 21:56 ч. UTC

Пазарно говорене

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16.05.2025 г., 21:56 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.05.2025 г., 21:54 ч. UTC

Топ новини

U.S. Loses Last Triple-A Credit Rating -- WSJ

16.05.2025 г., 21:22 ч. UTC

Пазарно говорене

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16.05.2025 г., 21:17 ч. UTC

Пазарно говорене

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16.05.2025 г., 21:17 ч. UTC

Топ новини

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16.05.2025 г., 21:05 ч. UTC

Пазарно говорене

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16.05.2025 г., 20:55 ч. UTC

Придобивния, сливания и поглъщания

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16.05.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Financial Services Roundup: Market Talk

16.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

16.05.2025 г., 20:37 ч. UTC

Топ новини

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16.05.2025 г., 20:33 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16.05.2025 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16.05.2025 г., 20:18 ч. UTC

Топ новини

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16.05.2025 г., 20:16 ч. UTC

Топ новини

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16.05.2025 г., 20:15 ч. UTC

Печалби

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16.05.2025 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

Henry Schein: William K. Daniel Joins Board

16.05.2025 г., 20:10 ч. UTC

Придобивния, сливания и поглъщания

Henry Schein: Strategic Investment by KKR Completed

16.05.2025 г., 20:05 ч. UTC

Придобивния, сливания и поглъщания

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16.05.2025 г., 19:38 ч. UTC

Пазарно говорене

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16.05.2025 г., 19:07 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Week Lower -- Market Talk

16.05.2025 г., 18:51 ч. UTC

Топ новини

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16.05.2025 г., 18:41 ч. UTC

Придобивния, сливания и поглъщания

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16.05.2025 г., 18:37 ч. UTC

Пазарно говорене

Gold Futures End Week on Negative Note -- Market Talk

16.05.2025 г., 18:35 ч. UTC

Топ новини

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16.05.2025 г., 18:32 ч. UTC

Топ новини

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16.05.2025 г., 18:28 ч. UTC

Пазарно говорене

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Kura Oncology Inc Прогноза

Ценова цел

By TipRanks

279.83% нагоре

12-месечна прогноза

Среден 22.6 USD  279.83%

Висок 40 USD

Нисък 10 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Kura Oncology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

10

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

5.575 / 6.6Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

177 / 382 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.